Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice

Journal of Immunology

Volumn 192, Issue 11, 2014, Pages 5434-5441

  Macagno, Marco ^a   Bandini, Silvio ^a   Stramucci, Lorenzo ^b   Quaglino, Elena ^a   Conti, Laura ^a   Balmas, Elisa ^a   Smyth, Mark J ^c,d   Lollini, Pier Luigi ^e   Musiani, Piero ^b   Forni, Guido ^a   Iezzi, Manuela ^b   Cavallo, Federica ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERFORIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INCIDENCE; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; FEMALE; IMMUNOSURVEILLANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SALIVARY GLAND CARCINOMA; TUMOR GROWTH;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PORE FORMING CYTOTOXIC PROTEINS; RATS; RECEPTOR, ERBB-2;

EID: 84901251487     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301248     Document Type: Article

References (32)

1. Galon, J., H. K. Angell, D. Bedognetti, and F. M. Marincola. 2013. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39: 11-26.
2. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
3. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
4. Koebel, C. M., W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. Smyth, and R. D. Schreiber. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907.
5. Smyth, M. J., K. Y. Thia, S. E. Street, D. MacGregor, D. I. Godfrey, and J. A. Trapani. 2000. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192: 755-760.
6. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNg and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
7. Street, S. E., Y. Hayakawa, Y. Zhan, A. M. Lew, D. MacGregor, A. M. Jamieson, A. Diefenbach, H. Yagita, D. I. Godfrey, and M. J. Smyth. 2004. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med. 199: 879-884.
8. Klement, G. L., D. Goukassian, L. Hlatky, J. Carrozza, J. P. Morgan, and X. Yan. 2012. Cancer therapy targeting the HER2-PI3K pathway: potential impact on the heart. Front. Pharmacol. 3: 113.
9. Mendelsohn, J., and J. Baselga. 2000. The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565.
10. Tagliabue, E., A. Balsari, M. Campiglio, and S. M. Pupa. 2010. HER2 as a target for breast cancer therapy. Expert Opin. Biol. Ther. 10: 711-724.
11. Ettl, T., C. Stiegler, K. Zeitler, A. Agaimy, J. Zenk, T. E. Reichert, M. Gosau, T. Kuhnel, G. Brockhoff, and S. Schwarz. 2012. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum. Pathol. 43: 921-931.
12. Gullick, W. J., A. C. Bottomley, F. J. Lofts, D. G. Doak, D. Mulvey, R. Newman, M. J. Crumpton, M. J. Sternberg, and I. D. Campbell. 1992. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein. EMBO J. 11: 43-48.
13. Quaglino, E., C. Mastini, G. Forni, and F. Cavallo. 2008. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr. Protoc. Immunol. Chapter 20: Unit 20.9.1-20.9.10.
14. Diodoro, M. G., E. Di Carlo, R. Zappacosta, M. Iezzi, A. Coletti, A. Modesti, T. D'Antuono, G. Forni, and P. Musiani. 2000. Salivary carcinoma in HER-2/neu transgenic male mice: an angiogenic switch is not required for tumor onset and progression. Int. J. Cancer 88: 329-335.
15. Rolla, S., C. Nicoló, S. Malinarich, M. Orsini, G. Forni, F. Cavallo, and F. Ria. 2006. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J. Immunol. 177: 7626-7633.
16. Rolla, S., F. Ria, S. Occhipinti, G. Di Sante, M. Iezzi, M. Spadaro, C. Nicolò, E. Ambrosino, I. F. Merighi, P. Musiani, et al. 2010. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J. Immunol. 184: 6124-6132.
17. Street, S. E., N. Zerafa, M. Iezzi, J. A. Westwood, J. Stagg, P. Musiani, and M. J. Smyth. 2007. Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res. 67: 5454-5460.
18. Bandini, S., C. Curcio, M. Macagno, E. Quaglino, M. Arigoni, S. Lanzardo, A. Hysi, G. Barutello, L. Consolino, D. L. Longo, et al. 2013. Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/ neu transgenic mice. OncoImmunology 2: e26137.
19. McClive, P. J., and A. H. Sinclair. 2001. Rapid DNA extraction and PCR-sexing of mouse embryos. Mol. Reprod. Dev. 60: 225-226.
20. Watson, C. J., and W. T. Khaled. 2008. Mammary development in the embryo and adult: a journey of morphogenesis and commitment. Development 135: 995-1003.
21. De Creus, A., K. Van Beneden, F. Stevenaert, V. Debacker, J. Plum, and G. Leclercq. 2002. Developmental and functional defects of thymic and epidermal V gamma 3 cells in IL-15-deficient and IFN regulatory factor-1-deficient mice. J. Immunol. 168: 6486-6493.
22. Nakazato, K., H. Yamada, T. Yajima, Y. Kagimoto, H. Kuwano, and Y. Yoshikai. 2007. Enforced expression of Bcl-2 partially restores cell numbers but not functions of TCRgd intestinal intraepithelial T lymphocytes in IL-15-deficient mice. J. Immunol. 178: 757-764.
23. Boggio, K., G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I. Rossi, P. Nanni, C. De Giovanni, et al. 1998. Interleukin 12- mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188: 589-596.
24. Peng, Y. P., Y. Zhu, J. J. Zhang, Z. K. Xu, Z. Y. Qian, C. C. Dai, K. R. Jiang, J. L.Wu,W. T. Gao, Q. Li, et al. 2013. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J. Transl. Med. 11: 262.
25. Gross, E., J. B. Sunwoo, and J. D. Bui. 2013. Cancer immunosurveillance and immunoediting by natural killer cells. Cancer J. 19: 483-489.
26. Quintana, E., M. Shackleton, M. S. Sabel, D. R. Fullen, T. M. Johnson, and S. J. Morrison. 2008. Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
27. Valent, P., D. Bonnet, R. De Maria, T. Lapidot, M. Copland, J. V. Melo, C. Chomienne, F. Ishikawa, J. J. Schuringa, G. Stassi, et al. 2012. Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer 12: 767-775.
28. Bonneville, M., R. L. O'Brien, and W. K. Born. 2010. gd T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10: 467-478.
29. Tang, Y., C. Peitzsch, H. N. Charoudeh, M. Cheng, P. Chaves, S. E. Jacobsen, and E. Sitnicka. 2012. Emergence of NK-cell progenitors and functionally competent NK-cell lineage subsets in the early mouse embryo. Blood 120: 63-75.
30. Rukavina, D., and E. R. Podack. 2000. Abundant perforin expression at the maternal-fetal interface: guarding the semiallogeneic transplant? Immunol. Today 21: 160-163.
31. Kusakabe, K., Z. L. Li, Y. Kiso, and Y. Otsuki. 2005. Perforin improves the morphogenesis of mouse placenta disturbed by IL-2 treatment. Immunobiology 209: 719-728.
32. Reardon, C., L. Lefrancois, A. Farr, R. Kubo, R. O'Brien, and W. Born. 1990. Expression of g/d T cell receptors on lymphocytes from the lactating mammary gland. J. Exp. Med. 172: 1263-1266.